Monitor for future commercial uptake metrics (e.g., number of patients treated, batch production rates) to assess ZEVASKYN's real-world adoption. The addition of a top-tier medical center may support long-term penetration, but current insider selling and lack of sales data suggest caution on near-term upside.
Price Chart
Executive Summary
Abeona Therapeutics announced the activation of NewYork-Presbyterian/Columbia University Irving Medical Center as its fifth Qualified Treatment Center for ZEVASKYN, a gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). This expansion increases patient access in the Northeast and strengthens commercial distribution of the therapy, though no new financial or clinical data was provided.
Key Facts
- NewYork-Presbyterian/Columbia University Irving Medical Center is now the fifth Qualified Treatment Center (QTC) for ZEVASKYN.
- ZEVASKYN is the first and only autologous cell sheet-based gene therapy approved for RDEB, a rare and severe genetic skin disorder.
- No financial figures, patient enrollment updates, or clinical results were disclosed in the release.
- The announcement focuses on commercial infrastructure expansion, not product performance or regulatory milestones.
Financial Impact
Minimal near-term financial impact; expands commercial footprint without immediate revenue disclosure.
Risk Factors
- Commercial execution risk: Limited number of QTCs may constrain patient access and revenue generation.
- Manufacturing scalability: Abeona must produce sufficient ZEVASKYN batches to meet demand across expanding centers.
- Market size uncertainty: RDEB is ultra-rare, limiting total addressable market potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3267338 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $5.47 $5.57 | ▲ +1.83% | ▲ +1.01% | $5.03 (−8.14%) |
Aug 14, 2026 6w ago | Institutional Cluster | $5.94 $6.06 | ▲ +2.02% | ▲ +3.21% | $5.03 (−15.40%) |
Aug 13, 2026 7w ago | 8-K | $6.35 $5.96 | ▼ −6.07% | ▼ −4.10% | $5.03 (−20.80%) |
Aug 13, 2026 7w ago | Press Release | $6.35 $5.96 | ▼ −6.07% | ▼ −4.10% | $5.03 (−20.80%) |
Jul 9, 2026 12w ago | Insider Cluster | $6.98 $7.02 | ▲ +0.57% | ▲ +1.13% | $5.03 (−28.01%) |
Jun 15, 2026 15w ago | Insider Cluster | $5.65 $5.72 | ▲ +1.24% | ▲ +3.47% | $5.03 (−11.06%) |
Jun 15, 2026 15w ago | Insider Cluster | $5.65 $5.72 | ▼ −1.24% | ▼ −3.47% | $5.03 (+11.06%) |
Jun 12, 2026 16w ago | 8-K | $5.53 $5.77 | ▲ +4.34% | ▲ +3.67% | $5.03 (−9.13%) |
Jun 10, 2026 16w ago | 8-K | $5.53 $5.65 | ▲ +2.17% | ▲ +1.74% | $5.03 (−9.13%) |
Jun 10, 2026 16w ago | Insider Cluster | $5.36 $5.65 | ▼ −5.41% | ▼ −1.98% | $5.03 (+6.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access